Abstract. Previous studies have indicated that caveolin-1 (Cav-1) is able to bind the signal transduction factor epidermal growth factor receptor (EGFR) to regulate its tyrosine kinase activity. The aim of the present study was to evaluate the clinical significance of Cav-1 gene expression in association with the expression of EGFR in patients with breast cancer. Primary breast cancer samples from 306 patients were analyzed for Cav-1 and EGFR expression using immunohistochemistry, and clinical significance was assessed using multivariate Cox regression analysis, Kaplan-Meier estimator curves and the log-rank test. Stromal Cav-1 was downregulated in 38.56% (118/306) of tumor tissues, whereas cytoplasmic EGFR and Cav-1 were overexpressed in 53.92% (165/306) and 44.12% (135/306) of breast cancer tissues, respectively. EGFR expression was positively associated with cytoplasmic Cav-1 and not associated with stromal Cav-1 expression in breast cancer samples; however, low expression of stromal Cav-1 was negatively associated with cytoplasmic Cav-1 expression in total tumor tissues, and analogous results were identified in the chemotherapy group. Multivariate Cox's proportional hazards model analysis revealed that, for patients in the estrogen receptor (ER)(+) group, the expression of stromal Cav-1 alone was a significant prognostic marker of breast cancer. However, in the chemotherapy, human epidermal growth factor receptor 2 (HER-2)(-), HER-2(+) and ER(-) groups, the use of combined markers was more effective prognostic marker. Stromal Cav-1 has a tumor suppressor function, and the combined marker stromal Cav-1/EGFR expression was identified as an improved prognostic marker in the diagnosis of breast cancer. Parenchymal expression of Cav-1 is able to promote EGFR signaling in breast cancer, potentially being required for EGFR-mediated initiation of mitosis.
Introduction
Breast cancer is the most common female malignancy worldwide and its incidence increases annually (1, 2) . The caveolin-1 (Cav-1) gene is a member of the caveolin gene family, which is located at chromosomal locus 7q31.1 (3, 4) , and encodes the Cav-1 protein, which is a principal component of plasma membrane caveolae (5, 6) . Cav-1 is expressed in various breast cell types, including mammary gland epithelial cells, fibroblasts, adipocytes, endothelial cells and smooth muscle cells (7) (8) (9) , and functions in tumorigenesis primarily through lipid transport, membrane transport, gene regulation and signal transduction (10) . Its abnormal expression in breast cancer, where it is a putative tumor suppressor (11) , is associated with the occurrence, progression and poor prognosis of breast cancer (12) (13) (14) . Epidermal growth factor receptor (EGFR) interacts directly with the caveolin-scaffolding domain through a caveolin-binding sequence motif located in the intracellular kinase domain of the receptor (5, 15) , and this interaction has been demonstrated to modulate EGFR-mediated signaling (16, 17) .
Cav-1 mutation or abnormal expression is able to positively regulate the expression of EGFR (15, 18, 19) , which is overexpressed in ~33% of breast cancers (20) . Abnormal activation of EGFR often indicates poor prognosis and has a marked association with differentiation and metastasis of tumor cells (21) (22) (23) (24) (25) (26) (27) . Importantly, EGFR is highly concentrated in caveolae membrane fractions and binds Cav-1 via a caveolin-binding motif of the kinase domain (15, 28, 29) .
Considering the prognostic capacity of EGFR in breast cancer, the wide expression of Cav-1 in numerous breast cancers and the association between them, the present study Combined caveolin-1 and epidermal growth factor receptor expression as a prognostic marker for breast cancer sought to use a combination approach analyzing two proteins as a combined prognostic marker for breast cancer, something which, to the best of our knowledge, has not previously been reported. ) for 20 min at room temperature, the sections were then stained with DAB (OriGene Technologies, Inc.) to detect the proteins for 2 min at 37˚C, followed by counterstaining with hematoxylin for 5 min at 37˚C. Slides were dehydrated through an ascending series of alcohols (from 85 and 95% until pure alcohol for 5 min) and mounted. IHC and scoring were performed using a light microscope at magnifications, x100 and x400, separately for all samples by two independent investigators without any prior knowledge of the clinicopathological data. Cumulative OS curves were generated according to the Kaplan-Meier estimator method, and the association between each of the variables and survival was assessed using the log-rank test in a univariate analysis. To identify independent predictors of survival, the parameters were then tested using the multivariate Cox's proportional hazards model.
Materials and methods

Tissue microarray (TMA)
.
Results
Expression of cytoplasmic EGFR and Cav-1 and stromal
Cav-1 in breast cancer tissues. Using IHC, the expression of cytoplasmic EGFR and Cav-1 and stromal Cav-1 was detected in patient breast tumor and adjacent normal breast tissues. As presented in Fig. 1 , cytoplasmic EGFR and Cav-1 were significantly overexpressed (P<0.001 and P= 0.007, respectively) in tumor tissues relative to adjacent normal tissues, whereas stromal Cav-1 appeared to be downregulated (P= 0.010). IHC analysis revealed that cytoplasmic EGFR and Cav-1 were overexpressed in 53.92% (165/306) and 44.12% (135/306), respectively, of tumor tissues, whereas stromal Cav-1 was downregulated in 38.56% (118/306) of tumor tissues.
Clinical significance of cytoplasmic EGFR and Cav-1 and stromal Cav-1 expression in breast cancer tissues. Downregulation of stromal Cav-1 in breast cancer was associated with differentiation (P= 0.050), p53 status (P= 0.001) and Ki-67 status (P= 0.042), but not with any of the other clinical parameters. Overexpression of cytoplasmic EGFR was positively associated with HER-2 (P= 0.015) and Ki-67 (P= 0.015) expression (data not shown). Statistical correlation analysis demonstrated that EGFR expression was positively correlated with cytoplasmic Cav-1 expression (r= 0.177; P= 0.002), but no correlation with stromal Cav-1 expression in tumor tissues was identified; however, low expression of stromal Cav-1 was negatively correlated with cytoplasmic Cav-1 expression in tumor tissues of total patients group (r=-0.325; P<0.001; Table II ). EGFR expression was positively correlated with cytoplasmic Cav-1 expression (r= 0.181; P= 0.005), but no correlation with stromal Cav-1 expression in tumor tissues was identified; however, low expression of stromal Cav-1 was positively correlated with cytoplasmic Cav-1 expression in tumor tissues of the total patients group (r=-0.272; P<0.001; Table III) .
Clinical significance of combined marker EGFR/stromal
Cav-1 expression in breast cancer tissues. Four patient subgroups were classified according to the combined expression status of EGFR and stromal Cav-1 (Fig. 2) . For OS and DFS, patient tissues with concordant high EGFR (P<0.001) and low stromal Cav-1 (P=0.008) expression (n=92) were observed isolated from those of the other three groups, classified as low EGFR/high stromal Cav-1 (n=60), high EGFR/high stromal Cav-1 (n=71) and low EGFR/low stromal Cav-1 (n=83). To simplify the data and illustrate a mechanistic framework, the four groups were consolidated into Cluster A [EGFR(+) and stromal Cav-1(-), n=92] and Cluster B [either EGFR(-) or stromal Cav-1(+), n=214]. Notably, there were significant associations with differentiation (P= 0.041), p53 status (P= 0.019) and PR status (P=0.036) for the Cluster A subgroup (data not shown).
OS univariate and multivariate analyses. The patients were divided into two further groups (adjuvant chemotherapy-treated patients, n=249; non-adjuvant chemotherapy-treated patients, n=57) on the basis of whether they received adjuvant Line of overall survival and disease-free survival representing concurrent EGFR(+) and stromal caveolin-1(-) isolated separately from the other three lines (P<0.001 and P= 0.008, respectively). EGFR, epidermal growth factor receptor; CI, confidence interval. Table IV . Univariate and multivariate analyses of OS and DFS in patients with chemotherapy group (n=249). ---------------------------------------------------------------------------------------------------------------- DFS, disease-free survival; EGFR, epidermal growth factor receptor; Cav-1, caveolin-1. Table V . Univariate and multivariate analyses of OS and DFS in patients with HER-2(-) expression (n=237).
-----------------------------------------------------------------------------------------------------------------------------------------------Univariate
Multivariate Univariate Fig. 3) . Notably, combined expression of Cav-1 and EGFR markers was the most marked independent prognostic factor in multivariate analysis, as presented in Fig. 3 . For non-adjuvant chemotherapy-treated patients, EGFR, stromal Cav-1 and combined expression of Cav-1 and EGFR markers no significant correlation with OS in the multivariate analysis was identified.
Multivariate --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Patients were divided into two groups on the basis of HER-2 and ER status. Multivariate analysis identified that differentiation, TNM clinical stage and combined markers were significant independent prognostic factors for OS of the HER-2(-) group (n=237) with HRs of 5.589 (95% CI, 1.863-16.766), 11.326 (95% CI, 1.545-83.025) and 3.287 (95% CI, 1.658-6.516), respectively (Table V;   Table VI . Univariate and multivariate analyses of overall survival in patients with HER-2(+) expression (n=69). (Table VII; Fig. 6 ). TNM clinical stage and combined markers were significant independent prognostic factors of OS of the ER(-) group (n=110) with HRs of 3.631 (95% CI, 1.768-7.456) and 5.020 (95% CI, 2.250-11.200), respectively (Table VIII; Fig. 7) . No significant correlation between EGFR, stromal Cav-1 and combined markers with DFS of ER(+) (n=188) or HER-2(+) (n=62) groups were identified in the multivariate analysis. However, the rates for DFS of the ER(-) group Table VII . Univariate and multivariate analyses of overall survival in patients with estrogen receptor(+) expression (n=196). Fig. 7 ).
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Discussion
Cav-1 is a primary scaffolding protein of the cell membrane whose abnormal stromal expression is associated with the occurrence, progression and prognosis of breast cancer (5,13), and Cav-1 negatively regulates EGFRs (17, 31) , further confirmed by data from the present study. In addition, it was revealed that Cav-1 is more effective as a breast cancer prognostic marker when its expression is combined with that of EGFR.
Multiple factors analysis of a series of variables revealed that, for patients in the ER(+) group, the expression of stromal Cav-1 alone is a significant prognostic marker of breast cancer. However, in the chemotherapy, HER-2(-), HER-2(+) and ER(-) groups, use of combined markers was more effective. Specifically, stromal Cav-1 expression combined with that of EGFR tends to have greater prognostic capacity than that of Cav-1 alone. Indeed, the data identified a consistent correlation among stromal Cav-1 and EGFR expression with clinical pathological features. This finding may be useful during the first step of prognostic screening as Cav-1 is readily detected in numerous breast cancer tumors.
Cav-1 is able to bind the signal transduction factor EGFR to regulate its tyrosine kinase activity and one of the notable findings is the ability of Cav-1 to regulate certain tyrosine kinase receptors (29) . Inactivated EGFRs are clustered within caveolae and leave this lipid raft structure upon activation and raft internalization is regulated by Cav-1 scaffolds that indirectly regulate EGFR (28) . In addition, oligomeric Cav-1 domains bind to inactive EGFR and prevent its activation (17) . It was revealed that Cav-1 in the parenchyma is negatively associated with stromal Cav-1 expression and positively correlated with EGFR expression. It has been demonstrated that Cav-1 is a tumor suppressor in breast cancer (32) . The combined results of these previous studies and our those of the present study suggest that Cav-1 has marked biological and clinical significance for EGFR(+) breast cancer, and the combination of stromal Cav-1 and EGFR expression in breast cancer is an improved prognostic indicator compared with either individually in tumors with a number of different receptor and pathological features.
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